Skip to main content
. 2015 Dec 28;12:S1–S110. doi: 10.1111/j.1470-9465.2006.12_4_1426.x

Study 1a Antifungal Prophylaxis in HSCT Recipients With GVHD
Study 2b Antifungal Prophylaxis in AML or MDS Patients With Neutropenia
Deaths, n (%) POS n=301 FLU n=299 log-Rank Test P value POS n=304 FLU or ITZ n=298 log-Rank Test P value
All cause mortality 76 (25) 84 (28) .376 44 (15) 64 (22) .035

IFI-related 4 (1) 12 (4) .046 5 (2) 15 (5) .021
a.

Deaths reported at end of study (day 168).

b.

Deaths reported up to 100 day postrandomisation (censoring time)